<p><strong>Pediatric Use</strong>: Clinical trials for safety and effectiveness in pediatric hemophilia A patients have not been conducted. The hemostatic efficacy of Alphanate has been studied in 20 pediatric subjects with VWD 18 years of age and under. Based on the data from a subset of these subjects, age had no effect on the pharmacokinetics of VWF:RCo<br />
<br />
<strong>Geriatric Use</strong>: No human or animal data. Use only if clearly needed</p>